Your search returned 6 results.

Results
	1.	Phase I trial of dasatinib and ixabepilone in patients with solid tumors. MedStar authors: Herbolsheimer, Pia M Jelinek, James S Kapoor, R Perry, David J Smith, Karen L Swain, Sandra M Verma, Nitin Veytsman, Irina PMID: 22392508 Citation: Investigational New Drugs. 31(1):92-8, 2013 Feb. Institution: MedStar Washington Hospital Center Washington Cancer Institute Department: Radiology Medline publication type: Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Herbolsheimer P, Jelinek J, Kapoor R, Perry D, Smith KL, Swain SM, Verma N, Veytsman I DOI: http://dx.doi.org/10.1007/s10637-012-9805-y Add to cart (remove)
	2.	A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. MedStar authors: Trivedi, Neel PMID: 29610115 Year: 2018 Citation: Blood Advances. 2(7):762-768, 2018 Apr 10 Institution: MedStar Washington Hospital Center Department: Hematology and Oncology Medline publication type: Journal Article Form of publication: Journal Article All authors: Cheson BD, Khan N, Ramzi P, Skarbnik A, Trivedi N, Ujjani C, Wang H DOI: https://dx.doi.org/10.1182/bloodadvances.2017015263 Add to cart (remove)
	3.	Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. MedStar authors: Kumar, Anjali S PMID: 26187751 Citation: Lancet Oncology. 16(8):957-66, 2015 Aug. Institution: MedStar Washington Hospital Center Department: Surgery/Colorectal Surgery Medline publication type: Clinical Trial, Phase II Journal Article Multicenter Study Research Support, N.I.H., Extramural Form of publication: Journal Article All authors: Avila K, Cataldo PA, Chow OS, Coutsoftides T, Dietz DW, Fichera A, Garcia-Aguilar J, Herzig DO, Hunt SR, Kumar AS, Marcet JE, Oommen S, Patil S, Polite BN, Smith DD, Stamos MJ, Ternent CA, Timing of Rectal Cancer Response to Chemoradiation Consortium, Varma MG DOI: http://dx.doi.org/10.1016/S1470-2045(15)00004-2 Add to cart (remove)
	4.	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors: Rao, Suman PMID: 29129441 Year: 2017 Citation: Lancet Oncology. 18(12):1600-1609, 2017 Dec Institution: MedStar Franklin Square Hospital Medline publication type: Journal Article Form of publication: Journal Article All authors: Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J DOI: https://dx.doi.org/10.1016/S1470-2045(17)30690-3 Add to cart (remove)
	5.	Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. MedStar authors: Barac, Ana PMID: 26439451 Year: 2016 Citation: Cancer. 122(1):124-30, 2016 Jan 1. Institution: MedStar Heart & Vascular Institute Medline publication type: Journal Article Research Support, N.I.H., Extramural Form of publication: Journal Article All authors: Atkins MB, Barac A, Freedman AN, Fu AZ, Jang S, Minasian L, Potosky AL, Tsai HT, Zheng C DOI: http://dx.doi.org/10.1002/cncr.29728 Add to cart (remove)
	6.	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors: Rao, Suman PMID: 30620668 Year: 2019 Citation: Journal of Clinical Oncology. 37(7):537-546, 2019 03 01. Institution: Medstar Franklin Square Medical Center Medline publication type: Journal Article Form of publication: Journal Article All authors: Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J DOI: https://dx.doi.org/10.1200/JCO.18.00149 Add to cart (remove)

Powered by Koha